<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515878</url>
  </required_header>
  <id_info>
    <org_study_id>2019</org_study_id>
    <nct_id>NCT01515878</nct_id>
  </id_info>
  <brief_title>Hemocontrol's Effectiveness on the Reduction of Cardiovascular Long-term EventS</brief_title>
  <acronym>HERACLES</acronym>
  <official_title>Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that a consistent use of the Hemocontrol TM biofeedback function improves
      long-term cardiovascular outcome, mediated by reduced hypertension due to fluid overload and
      by reduced incidence of intradialytic hypotensive episodes
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>The primary objective will be assessed by the incidence rate of Fatal and not fatal cardiovascular events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular morbidity</measure>
    <time_frame>36 months</time_frame>
    <description>Number of hospital admissions evaluated as annual hospitalization rate related to: Non fatal myocardial infarction, New-onset angina, Non fatal stroke, Congestive heart failure, Transient ischemic attack, Pulmonary oedema
Length of stay during hospitalization;
Number of extra dialysis or prolonged dialysis due to fluid overload.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure control</measure>
    <time_frame>36 months</time_frame>
    <description>Blood pressure control:
Predialysis blood pressure measurements
Home blood pressure self assessment
Antihypertensive therapy changes
Proportion of patients achieving adequate blood pressure control
Intradialytic acute hypotension:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life and dialysis tolerance evaluated with questionnaire.</measure>
    <time_frame>36 months</time_frame>
    <description>Questions of the KDQOL36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dry weight management</measure>
    <time_frame>36 months</time_frame>
    <description>Optional when available at site: Hydration status estimated by Cardiothoracic index or BNP or BIA at baseline and each 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">396</enrollment>
  <condition>Kidney Failure Chronic</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Dialysis with BVT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dialysis using the BVT monitor biofeedback called Hemocontrol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional dialysis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional dialysis without blood volume tracking or similar therapies</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemocontrol</intervention_name>
    <description>Blood Volume Tracking system using biofeedback</description>
    <arm_group_label>Dialysis with BVT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age more than 65 years old

          2. Arterial Hypertension: predialysis SBP &gt;140 mmHg and/or DBP &gt;90 mmHg in at least 50%
             over the previous month dialysis sessions or receiving at least one antihypertensive
             pharmacological drug including diuretics, disregarded blood pressure value

          3. On a three times per week hemodialysis schedule

          4. Time on hemodialysis less than 6 months

          5. Able to measure their blood pressure at home (by themselves or with the aid of the
             care giver)

          6. Signed informed consent

        Exclusion Criteria:

          1. Active neoplastic disease

          2. Mental illness

          3. Pregnancy

          4. Single needle treatment

          5. Inability, as judged by the investigator, to follow or understand the protocol
             instructions

          6. Blood flow rate less than 200 mL/min

          7. Patients who at the time of recruitment need clinical indication for special renal
             replacement therapies and/or on treatment with one of the following modalities: HDF or
             similar diffusive-convective therapies, treatment time &gt;5h, blood temperature control,
             isolated UF profiling of Na/UFR

          8. Patients with a life expectancy shorter than 6 months

          9. Patients in a list for transplant within the next 6 months

         10. Predialysis Hemoglobin level greater than 13.5 g/dl

         11. History of major cardiovascular events during run in period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Mac Rae, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Calgary hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hafedh Fessi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>APHP Tenon, Paris France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Buades, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Majorca hospital, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Mancini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AOSP, Bologna Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Santoro, Pf</last_name>
    <role>Study Chair</role>
    <affiliation>AOSP, Bologna Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Santoro, Pf</last_name>
    <phone>+39 051 6362 430</phone>
    <email>antonio.santoro@aosp.bo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helena Mancini, MD</last_name>
    <email>elena.mancini@aosp.bo.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Health Regional hospital</name>
      <address>
        <city>Calgary</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Mac Rae, MD</last_name>
      <email>jennifer.macrae@calgaryhealthregion.ca</email>
    </contact>
    <investigator>
      <last_name>Jennifer Mac Rae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon, APHP</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Santoro, Pf</last_name>
      <phone>+39 051 63 62 430</phone>
      <email>antonio.santoro@aosp.bo.it</email>
    </contact>
    <contact_backup>
      <last_name>Elena Mancini, MD</last_name>
      <email>elena.mancini@aosp.bo.it</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Santoro, Pf</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Mancini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>July 4, 2012</last_update_submitted>
  <last_update_submitted_qc>July 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi</investigator_affiliation>
    <investigator_full_name>Antonio Santoro</investigator_full_name>
    <investigator_title>Professor, MD, Chief of Nephrology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

